Intrauterine contraception in diabetic women.
The results of intrauterine contraception using four different types of Antigen devices in 118 insulin-treated diabetic women are reported. The patients were followed for a total of 24 months. Cumulative closure rates for the 1st year were as follows: pregnancy, 3.5; expulsion, 13.1; removal for bleeding and/or pain, 7.9; and planned pregnancy, 1.2, giving a continuation rate of 74.3. Cumulative closure rates after 24 months were as follows: pregnancy, 6.5; expulsion, 14.4; removal for bleeding and/or pain, 17.1; and planned pregnancy, 8.3, giving a continuation rate of 56.7. These results are not significantly different from those found by us in nondiabetic women, No serious side effects occurred, in particular no pelvic inflammations or perforations. Intrauterine contraception using the Antigon appears to be a well-suited method for diabetic women.
D003920:Diabetes Mellitus; D005260:Female; D006801:Humans; D007434:Intrauterine Devices / Q000009:adverse effects; D011247:Pregnancy